Nirsevimab and Abrysvo Update for the 2024-2025 Respiratory Season

• 2024

  Log in to bookmark this resource.

  Log in

---

Access Resources

• SummaryEN
• Ask aRCie About This Resource

About

This webpage provides an update on both infant nirsevimab (Beyfortus®) and maternal RSVpreF (Abrysvo™) administration and planning considerations. Infants can be protected against RSV through maternal RSVpreF vaccination during pregnancy or nirsevimab administration for the infant. Most infants do not require both forms of protection. Nirsevimab is a long-acting monoclonal antibody given to infants to prevent severe RSV disease, and implementing newborn nirsevimab immunization is recommended for positive health impacts on children. It includes information about availability in Ohio.

---

Tags

Focus Area: Infectious Disease

Audiences: Families & Children; Nurses; Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Nirsevimab Library

Keywords: Infant; Ohio; Pregnant Women; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Antibodies, Monoclonal, Humanized

Institutions: Ohio Department of Health

---

More like this

Get the Facts About Candida auris 2025 · New York State Department of Health EZIZ: Measles Resources 2024 · California Department of Public Health Meeting Summary: State and Local Implementation Strategies for Increasing Access to Contraception During Zika Preparedness and Response — United States, September 2016 2017 · Centers for Disease Control and Prevention (CDC), Association of Schools & Programs of Public Health

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---